SECONDARY ACUTE MYELOID LEUKEMIA
Clinical trials for SECONDARY ACUTE MYELOID LEUKEMIA explained in plain language.
Never miss a new study
Get alerted when new SECONDARY ACUTE MYELOID LEUKEMIA trials appear
Sign up with your email to follow new studies for SECONDARY ACUTE MYELOID LEUKEMIA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Could a Gene-Targeting drug boost chemo for older leukemia patients?
Disease control CompletedThis study tested whether adding a drug called oblimersen to standard chemotherapy (daunorubicin and cytarabine) helps older adults (60+) with untreated acute myeloid leukemia live longer or achieve remission. About 500 participants were randomly assigned to receive chemo with or…
Matched conditions: SECONDARY ACUTE MYELOID LEUKEMIA
Phase: PHASE3 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 16, 2026 22:49 UTC
-
Tailored therapy boosts hope for older leukemia patients
Disease control CompletedThis study looked at whether matching treatment to a patient's genetic risk and overall health can improve outcomes for older adults (60+) with acute myeloid leukemia. Participants received either standard intensive or milder chemotherapy based on their personal risk profile. The…
Matched conditions: SECONDARY ACUTE MYELOID LEUKEMIA
Phase: PHASE2 • Sponsor: University of Nebraska • Aim: Disease control
Last updated Jun 16, 2026 22:36 UTC
-
New Two-Step transplant shows promise for tough blood cancers
Disease control CompletedThis study tested a two-step stem cell transplant for people with high-risk blood cancers like leukemia and lymphoma. First, patients got low-dose chemotherapy and radiation to prepare the body. Then, they received donor stem cells and immune cells to help destroy remaining cance…
Matched conditions: SECONDARY ACUTE MYELOID LEUKEMIA
Phase: PHASE2 • Sponsor: Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University • Aim: Disease control
Last updated Jun 16, 2026 12:51 UTC
-
New combo therapy shows promise for tough leukemia
Disease control CompletedThis study tested a new drug called uproleselan added to standard chemotherapy for people with a specific type of leukemia (secondary AML that has been treated before). The goal was to find the best dose and see how well the combination works. 37 adults took part, and the study l…
Matched conditions: SECONDARY ACUTE MYELOID LEUKEMIA
Phase: PHASE1, PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Jun 15, 2026 19:05 UTC
-
New drug combo shows promise in Tough-to-Treat leukemia
Disease control CompletedThis early-phase study tested a combination of two drugs, pevonedistat and decitabine, in 12 adults with high-risk acute myeloid leukemia (AML). The main goal was to find the safest dose and check for side effects. Researchers also looked at whether the treatment helped shrink or…
Matched conditions: SECONDARY ACUTE MYELOID LEUKEMIA
Phase: PHASE1 • Sponsor: City of Hope Medical Center • Aim: Disease control
Last updated Jun 15, 2026 18:57 UTC
-
Experimental combo shows promise in tough leukemia cases
Disease control CompletedThis early-phase study tested a combination of two drugs—veliparib and temozolomide—in 66 adults with acute leukemias that had come back or not responded to standard treatment. The goal was to find the safest dose and see how well the combination worked. Veliparib blocks a repair…
Matched conditions: SECONDARY ACUTE MYELOID LEUKEMIA
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 12, 2026 12:07 UTC
-
New hope for kids with tough leukemia: experimental combo tested
Disease control CompletedThis early-phase study tested a combination of three chemotherapy drugs (CPX-351 and gemtuzumab ozogamicin) in children whose acute myeloid leukemia (AML) had come back or didn't respond to standard treatment. The main goals were to find the best dose and check for side effects. …
Matched conditions: SECONDARY ACUTE MYELOID LEUKEMIA
Phase: PHASE1 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Jun 08, 2026 13:08 UTC
-
New liposome combo shows promise for Tough-to-Treat leukemia
Disease control CompletedThis study tested a new formulation of two chemotherapy drugs (CPX-351) in 56 adults with newly diagnosed acute myeloid leukemia (AML) who were at high risk of not responding to standard treatment. The goal was to find the best dose and see how well it worked to stop cancer cells…
Matched conditions: SECONDARY ACUTE MYELOID LEUKEMIA
Phase: PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Jun 01, 2026 18:06 UTC
-
New donor cell therapy shows promise for tough blood cancers
Disease control CompletedThis study tested an experimental treatment for people with myelodysplastic syndrome (MDS) or secondary acute myeloid leukemia (AML) whose first therapy stopped working. Nineteen adults received a special infusion of immune cells from a mismatched unrelated donor, designed to att…
Matched conditions: SECONDARY ACUTE MYELOID LEUKEMIA
Phase: PHASE1, PHASE2 • Sponsor: H. Lee Moffitt Cancer Center and Research Institute • Aim: Disease control
Last updated Jun 01, 2026 17:55 UTC
-
Can a simple bone marrow test predict who will beat High-Risk leukemia?
Knowledge-focused CompletedThis study looked at 39 adults with high-risk acute myeloid leukemia (AML) to see if certain markers in their bone marrow could predict how well they would respond to a combination of the drug sirolimus and standard chemotherapy. The goal was to find out if changes in these marke…
Matched conditions: SECONDARY ACUTE MYELOID LEUKEMIA
Phase: PHASE2 • Sponsor: Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University • Aim: Knowledge-focused
Last updated Jun 01, 2026 18:01 UTC